EWTXEdgewise Therapeutics, Inc.
Price
+174%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 2% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for EWTX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
Early in the founding of Edgewise, we identified a unique set of cardiovascular molecules as part of a skeletal muscle counter-screen. We initiated our cardiovascular program with EDG-7500 identified as our lead candidate, a molecule with unique characteristics. EDG-7500 is a novel oral, selective, cardiac sarcomere modulator (CSM), specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) without impacting systolic function.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Edgewise Therapeutics Reports Second Quarter.Earnings release · press release
- Jul 16, 2026On May 31, 2026, Edgewise Therapeutics, Inc. (“Edgewise”Material event (exhibits only) · press release
- Jul 13, 2026On July 10, 2026, Edgewise Therapeutics, Inc. (the “Company”) completed the previously announced acquisition of the Company’s sevasemten compound and certain other related assets collectively constituting the Company’s muscular dystrophy program (the “Program”) by Servier Pharmaceuticals LLC and Les Laboratoires …Acquisition or disposition completed · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.